Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam Pharmaceuticals Prices Public Offering of Common Stock

Business Wire January 15, 2013

Alnylam Pharmaceuticals Announces Proposed Public Offering of $125 Million of Common Stock

Business Wire January 14, 2013

The Reason It Trades, What's Moving DNDN, ISIS and ALNY

Marketwired January 14, 2013

Alnylam Provides Key 2013 - 2014 Goals for RNAi Therapeutics Pipeline

Business Wire January 6, 2013

Regulus to Present at 31st Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2013

Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Business Wire January 3, 2013

Alnylam to Webcast Presentation at 31st Annual J.P. Morgan Healthcare Conference

Business Wire January 2, 2013

Regulus Announces Addition to Russell 2000 Index

PR Newswire December 20, 2012

Tekmira up 10% on litigation settlement news

Stockhouse Editorial November 13, 2012